Company / Cash & Equivalents
CONMED Corporation Cash & Equivalents History
FY2016-FY2018 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$17.5M
FY2018
5-year range
-
FY2016-FY2018
Trend
-46.3%
vs FY2017
Sector context
#147 of 148
Health Care
What the data says
Among 148 Health Care companies, CONMED Corporation is in the bottom 1% for cash & equivalents. Declined from $27M to $18M over the past 2 years.
Based on SEC 10-K filings.
$18M in FY2018.
Declined from $27M to $18M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 1% in Health CareTop 99% of 148This company $17.5M Sector average $1.2B
▼
-98.5% below sector average
Key checks
Key Insights
- In FY2018, cash & equivalents decreased 46.3% year-over-year.
- Ranks #147 out of 148 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | $17.5M | -46.3% |
| FY2017 | $32.6M | +18.9% |
| FY2016 | $27.4M | -62.2% |
As of FY2018 · SEC 10-K · Updated Jul 4, 2026